

Name of listed company: Chugai Pharmaceutical Co., Ltd.
 Code number: 4519 (1st Section of Tokyo Stock Exchange)
 Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
 President & CEO: Osamu Nagayama
 Inquiries to: Nobuyuki Chiba, General Manager,
 Corporate Communications Dept.
 Tel: +81-(0)3-3273-0881

Revision of Financial Outlook for Fiscal Year 2010 (January 1 – December 31, 2010)

October 22, 2010 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama] announced today that the company revised the full year financial outlook for the fiscal year 2010 (January – December, 2010), originally released on February 3, 2010.

1. Revision of the consolidated financial outlook for the fiscal year 2010 (January – December, 2010)

(Millions of yen)

	Revenues	Operating Income	Recurring Profit	Net Income	Net Income Per Share
Original Outlook (A) (Released on Feb. 3, 2010)	418,500	70,000	70,500	44,000	¥80.85
Revised Outlook (B)	395,800	70,000	68,700	43,000	¥79.02
Variance (B-A)	(22,700)	0	(1,800)	(1,000)	
(% Change)	(5.4)	0	(2.6)	(2.3)	
Full year ended Dec. 31, 2009	428,947	82,612	90,395	56,634	¥104.00

2. Reason for the revisions

The sales forecasts for the products such as an anti-influenza agent Tamiflu, an anti-VEGF agent Avastin, a 5-HT₃ receptor antagonist/antiemetic agent Kytril, a recombinant human erythropoietin Epogin, a peginterferon alfa-2a Pegasys, an anti-viral agent Copegus, and export sales forecast for an anti-human IL-6 receptor Actemra are revised in light of the size of the influenza epidemic in the winter 2009/2010 as well as sales trend of major products up to September. For details, please refer to the attached table.

In addition, the full year consolidated forecast is also revised after considering ongoing cost savings in SG&A and the impacts from foreign exchange fluctuations. The revised forecast for the fourth quarter is based on an updated foreign exchange rate assumption: 1CHF = 85 JPY and 1EUR = 119 JPY.

* The company bases its forecasts on assumptions that are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties such as the size of the influenza epidemic.

<Reference> Revision of the full year sales outlook by products for the fiscal year 2010

(Billions of yen)

	Original Outlook	Revised Outlook	Variance	(% Change)
Sales	414.0	390.8	(23.2)	(5.6)
Excl. Tamiflu	375.3	357.8	(17.5)	(4.7)
Domestic	334.6	324.6	(10.0)	(3.0)
Oncology field	140.2	139.9	(0.3)	(0.2)
Avastin	47.9	51.2	3.3	6.9
Herceptin	24.7	24.7	0.0	0.0
Rituxan	23.4	22.5	(0.9)	(3.8)
Xeloda	10.9	11.3	0.4	3.7
Neutrogen	11.6	10.7	(0.9)	(7.8)
Tarceva	7.7	7.7	0.0	0.0
Kytril	7.8	6.0	(1.8)	(23.1)
Femara	3.6	3.2	(0.4)	(11.1)
Other products	2.5	2.5	0.0	0.0
Bone and joint diseases field	64.2	63.5	(0.7)	(1.1)
Evista	18.1	18.1	0.0	0.0
Actemra	15.1	15.1	0.0	0.0
Suvenyl	14.3	13.9	(0.4)	(2.8)
Alfarol	12.8	12.5	(0.3)	(2.3)
Other products	4.0	4.0	0.0	0.0
Renal diseases field	59.3	58.3	(1.0)	(1.7)
Epogin	42.2	41.2	(1.0)	(2.4)
Oxarol	11.6	11.6	0.0	0.0
Renagel	4.9	4.9	0.0	0.0
Other products	0.7	0.7	0.0	0.0
Transplant, immunology & infectious diseases field	31.9	25.8	(6.1)	(19.1)
Pegasys	14.8	10.5	(4.3)	(29.1)
Copegus	7.1	4.6	(2.5)	(35.2)
Rocephin	4.9	5.4	0.5	10.2
CellCept	5.0	5.0	0.0	0.0
Other products	0.3	0.3	0.0	0.0
Others field	38.9	37.1	(1.8)	(4.6)
Sigmart	13.7	13.1	(0.6)	(4.4)
Other products	25.2	24.0	(1.2)	(4.8)
Overseas	40.7	33.2	(7.5)	(18.4)
Neutrogen	17.9	17.0	(0.9)	(5.0)
Actemra	19.7	12.8	(6.9)	(35.0)
Sigmart	1.7	2.2	0.5	29.4
Other products	1.4	1.2	(0.2)	(14.3)
Tamiflu	38.7	33.0	(5.7)	(14.7)
Ordinary sales	20.5	16.4	(4.1)	(20.0)
Govt. stockpile etc.	18.2	16.6	(1.6)	(8.8)
Other operating revenues	4.5	5.0	0.5	11.1
Revenues (Total)	418.5	395.8	(22.7)	(5.4)
Domestic	373.8	358.0	(15.8)	(4.2)
Overseas	44.7	37.8	(6.9)	(15.4)

Note: Amounts are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on amounts shown.